SEC Form 424B3 filed by Kairos Pharma Ltd.
$KAPA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Event to feature principal investigators from the trial Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company's interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Interested participants can sign-up to receive the webcast link here. "The safety results of the trial are an important catalyst as we prepare for the announcement of our interim efficacy
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference which takes place September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain. Dr. Reckamp's presentation, "Combination of Osimertinib and Carotuximab for Advanced, EFGR-Mutated Non-Small Cell Lung Cancer Patients," focuses on combination therapy of ENV105 with osimertinib for the treatment of non-small cell lung cancer. More information on the
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel. Presentation Date: September 5, 2025 Time: Available on-demand starting at 7:00 AM Eastern Time Webcast Link: https://journey.ct.events/view/567df3a2-9eaf-4575-bb61-3cdabd42346f A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A r
8-K - Kairos Pharma, LTD. (0001962011) (Filer)
8-K - Kairos Pharma, LTD. (0001962011) (Filer)
424B3 - Kairos Pharma, LTD. (0001962011) (Filer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
3 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)